Sanofi's R&D Leadership Change and the Challenges for the New Leader

French pharmaceutical giant Sanofi has made a significant change in its R&D leadership to address pipeline setbacks. Houman Ashrafian, who led research since 2023, has left the company, and Paulo Fontoura, formerly of Roche and Chief Medical Officer (CMO) at Xaira Therapeutics, will take over on September 1st. Sanofi has faced pressure from shareholders due to recent pipeline failures, including the clinical failure of the CIDP treatment rilipubart. This leadership change is seen as a strategic move to revitalize the company. The new leader will report to Belén Garijo, CEO, and will need to leverage AI and precision medicine to reshape the company's growth trajectory.

Merck Demonstrates Asset Value Through the Acquisition of Prometheus

The acquisition of Prometheus Biosciences by Merck & Co. for $10.8 billion in 2023 is starting to yield results. Merck's key immunology pipeline drug, tulisokibart, has met primary and key secondary endpoints in a Phase 3 trial (ATLAS-UC Induction-only study) for patients with moderate-to-severe active ulcerative colitis. This demonstrates that the TL1A protein inhibition mechanism targeted by tulisokibart provides effective therapeutic benefits in real-world patients. Merck plans to work closely with regulatory authorities based on these results and aims to secure a next-generation blockbuster pipeline in the immunology field to counter the upcoming patent expiration of its immuno-oncology drug, Keytruda.

Definium Therapeutics' Psychedelic Therapy Achieves Positive Phase 3 Results

The stock price of Definium Therapeutics, a leader in the psychedelic biotechnology field, surged 50% after announcing positive Phase 3 results. Definium successfully demonstrated the efficacy and safety of DT120, an oral disintegrating tablet (ODT) formulation of LSD, in a Phase 3 trial (Emerge study) for patients with major depressive disorder. Marc Goodman, an analyst at Leerink Partners, has raised the peak sales forecast for major depressive disorder to $1.5 billion to $2.0 billion. These results represent a positive turning point for the psychedelic therapy market, which has been volatile due to regulatory approval uncertainty and the release of clinical data, and could pave the way for its integration into mainstream medicine.

Lilly and BioArctic Partner to Develop Brain-Penetrating Platform

Eli Lilly has entered into an $800 million co-research agreement with Swedish biotech BioArctic to develop therapies for neurological disorders. The deal combines Lilly's proprietary drug candidates with BioArctic's innovative brain transporter technology, designed to enable drugs to rapidly cross the blood-brain barrier and reach their targets. BioArctic will receive an upfront payment of $30 million, and may receive up to $770 million in milestone payments and royalties based on future development progress. Eli Lilly will lead global commercialization and subsequent clinical development, aiming to strengthen its dominance in the neurodegenerative disease area.

Trend of Streamlining New Drug R&D in the Pharmaceutical Industry

The global pharmaceutical industry is increasingly adopting a two-pronged strategy of internal resource reallocation and mergers and acquisitions (M&A) of validated pipelines to improve efficiency. Sanofi's R&D leadership change and Merck's successful Phase 3 results for tulisokibart demonstrate that securing innovative new drugs early through open innovation is a key to the survival of big pharma companies. In the future, big pharma companies are likely to focus on conducting early-stage development in-house and acquiring promising late-stage pipeline assets or licensing in key technologies such as blood-brain barrier penetration.